During TIDES: Oligonucleotide & Peptide Therapeutics, San Diego, USA, meet our experts to learn more about our oligonucleotide analytical development services. 20 -23 May 2019,
During TIDES: Oligonucleotide & Peptide Therapeutics 2019, Intertek will present on analytical development strategies which help to accelerate oligonucleotide product development from early characterisation to late-stage development & commercialization. Meet our team in San Diego, USA. Contact us to arrange a meeting during the event.
Case Study: Identification Testing by Accurate Mass and MS/MS Sequencing
Case Study: Oligonucleotide Identification, Assay and Impurities
Case Study: Determination of Melting Temperature for Oligonucleotide Duplexes using NMR
Article Download: Analytical challenges in the oligonucleotide characterisation
White Paper: Analytical Strategies for Quality Control of Oligonucleotide Therapeutics
With a growing global development pipeline of oligonucleotide therapeutics to treat a variety of disease targets, overcoming the challenges of innovation, regulatory authorization, production and the inherent complexity of oligos is critical to success. Contact our experts in oligonucleotide analysis and bioanalysis, to discuss our regulatory-driven, phase-appropriate characterization and biophysical analysis in support of CMC programs which GMP and CMC laboratory services, pharmaceutical analysis, quality control analysis, elemental impurities, extractables and leachables, stability programs, inhalation drug development, method development and method validation will be available to review your challenges and discuss and how our unrivalled expertise can help you to accelerate the development timelines.
Need help or have a question?